LONDON, January 24, 2019 /PRNewswire/ --
Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029
Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 160-page report you will receive 86 charts- all unavailable elsewhere.
The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
Global Asthma & COPD Therapies Market forecasts from 2019-2029
Profiles of the leading 20 asthma & COPD companies: Aerocrine (Circassia) ALK-Abello A/S Amphastar Pharmaceuticals, Inc. AstraZeneca Boehringer Ingelheim Chiesi Farmaceutici Cipla GlaxoSmithKline Lallemand Pharma International Merck MundiPharma Novartis Pulmatrix Roche Sanofi/Regeneron Sunovion Teva Theravance Biopharma|Mylan Inc. Vectura Group plc Verona Pharma plc
The content of each profile differs, depending on the organization. In general, a profile gives the following information: An overview and analysis of the company A portfolio of the company's marketed product and product pipeline Financial Information Revenue forecast from 2019-2029 Recent developments Future Outlook
This report discusses factors that drive and restrain the asthma and COPD market.
Visiongain's study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.
Buy our report today Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast
To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/pharma-leader-series-top-20-asthma-copd-companies-2019-2029/
Did you know that we also offer a report add-on service? Email [email protected] to discuss any customized research needs you may have.
Aerocrine (Circassia) ALK-Abello A/S American College of Chest Physicians (ACCP) Amphastar Pharmaceuticals, Inc. AstraZeneca Boehringer Ingelheim Chiesi Farmaceutici Ciba-Geigy Cipla Committee for Medicinal Products for Human Use (CHMP) Dainippon Sumitomo Pharma America, Inc. Dermira Inc. European Medicines Agency (EMA) European Respiratory Society (ERS) GlaxoSmithKline (GSK) Glenmark Hikma Innovata plc Innoviva, Inc. Japanese Ministry of Health, Labour and Welfare Lallemand Pharma International Medicines and Healthcare products Regulatory Agency (MHRA) Merck Monitored Therapeutics, Inc. (MTI) MundiPharma Mylan National Institute for Health and Care Excellence (NICE) Novartis Pulmatrix Regeneron Roche Sandoz Sanofi Sepracor Inc. Sorrento Sunovion Teva Theravance Biopharma|Mylan Inc. Torii Vectura Group plc Verona Pharma plc
To see a report overview please e-mail Sara Peerun on [email protected]
SOURCE Visiongain
Advertisement
Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029
Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast
Advertisement
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 160-page report you will receive 86 charts- all unavailable elsewhere.
The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
Global Asthma & COPD Therapies Market forecasts from 2019-2029
Profiles of the leading 20 asthma & COPD companies: Aerocrine (Circassia) ALK-Abello A/S Amphastar Pharmaceuticals, Inc. AstraZeneca Boehringer Ingelheim Chiesi Farmaceutici Cipla GlaxoSmithKline Lallemand Pharma International Merck MundiPharma Novartis Pulmatrix Roche Sanofi/Regeneron Sunovion Teva Theravance Biopharma|Mylan Inc. Vectura Group plc Verona Pharma plc
The content of each profile differs, depending on the organization. In general, a profile gives the following information: An overview and analysis of the company A portfolio of the company's marketed product and product pipeline Financial Information Revenue forecast from 2019-2029 Recent developments Future Outlook
This report discusses factors that drive and restrain the asthma and COPD market.
Visiongain's study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.
Buy our report today Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast
To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/pharma-leader-series-top-20-asthma-copd-companies-2019-2029/
Did you know that we also offer a report add-on service? Email [email protected] to discuss any customized research needs you may have.
Aerocrine (Circassia) ALK-Abello A/S American College of Chest Physicians (ACCP) Amphastar Pharmaceuticals, Inc. AstraZeneca Boehringer Ingelheim Chiesi Farmaceutici Ciba-Geigy Cipla Committee for Medicinal Products for Human Use (CHMP) Dainippon Sumitomo Pharma America, Inc. Dermira Inc. European Medicines Agency (EMA) European Respiratory Society (ERS) GlaxoSmithKline (GSK) Glenmark Hikma Innovata plc Innoviva, Inc. Japanese Ministry of Health, Labour and Welfare Lallemand Pharma International Medicines and Healthcare products Regulatory Agency (MHRA) Merck Monitored Therapeutics, Inc. (MTI) MundiPharma Mylan National Institute for Health and Care Excellence (NICE) Novartis Pulmatrix Regeneron Roche Sandoz Sanofi Sepracor Inc. Sorrento Sunovion Teva Theravance Biopharma|Mylan Inc. Torii Vectura Group plc Verona Pharma plc
To see a report overview please e-mail Sara Peerun on [email protected]
SOURCE Visiongain
